Carcinoma, Non-Small-Cell Lung

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Sotorasib is an inhibitor of the RAS GTPase family. The molecular formula is C<span class="Sub">30</span>H<span class="Sub">30</span>F<span class="Sub">2</span>N<span class="Sub">6</span>O<span class="Sub">3</span>, and the molecular weight is 560.6 g/mol. The chemical name of sotorasib is 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one.</p><p>The chemical structure of sotorasib is shown below:</p><div class="Figure"><img alt="Chemical Structure" src="lumakras-01.jpg"/></div><p>Sotorasib has pKa values of 8.06 and 4.56. The solubility of sotorasib in the aqueous media decreases over the range pH 1.2 to 6.8 from 1.3 mg/mL to 0.03 mg/mL.</p><p>LUMAKRAS is supplied as film-coated tablets for oral use containing 320 mg, 240 mg or 120 mg of sotorasib. Inactive ingredients in the tablet core are microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. The film coating material consists of polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow and iron oxide red (320 mg tablet only).</p></section>

LUMAKRAS

sotorasib

sotorasib 120 MG Oral Tablet

Lumakras

sotorasib 120 MG Oral Tablet [Lumakras]

sotorasib 320 MG Oral Tablet

sotorasib 320 MG Oral Tablet [Lumakras]

sotorasib 240 MG Oral Tablet

sotorasib 240 MG Oral Tablet [Lumakras]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information

How to Order Lumakras

Lumakras Access Guide 

Lumakras PA Checklist 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity

Benefit Verification & PA Form

Enroll in Patient Savings Program 

Amgen SupportPlus Enrollment Form 

Patient Brochure 

Other HCP Resources 

About Lumakras 

Taking Lumakras 

Side Effects

Patient Resources 

Patient Treatment Journal

Considerations For Your Next Doctor's Appointment 

Instructions For Use:  KRAS G12C Positive Non-Small Cell Lung Cancer 